Home » Stocks » ATRS

Antares Pharma, Inc. (ATRS)

Stock Price: $4.01 USD -0.12 (-2.91%)
Updated Apr 16, 2021 4:00 PM EDT - Market closed
Market Cap 674.33M
Revenue (ttm) 149.60M
Net Income (ttm) 56.20M
Shares Out 166.07M
EPS (ttm) 0.33
PE Ratio 12.15
Forward PE 15.75
Dividend n/a
Dividend Yield n/a
Trading Day April 16
Last Price $4.01
Previous Close $4.13
Change ($) -0.12
Change (%) -2.91%
Day's Open 4.16
Day's Range 3.97 - 4.17
Day's Volume 734,641
52-Week Range 2.39 - 5.07

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

In my opinion, choosing U.S.-listed securities that have the following characteristics represents a solid starting point when looking for potential value opportunities:

Other stocks mentioned: HLF, THRY
1 week ago - GuruFocus

Antares Pharma (ATRS) delivered earnings and revenue surprises of -25.00% and 7.99%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Shares of Antares Pharma (NASDAQ:ATRS) were unchanged after the company reported Q4 results. Quarterly Results Earnings per share were flat 0.00% over the past year to $0.03, which were in line with the...

1 month ago - Benzinga

EWING, N.J., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a pharmaceutical technology company, today announced that Robert F. Apple, President and Chief Executi...

1 month ago - GlobeNewsWire

EWING, N.J., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a pharmaceutical technology company, today announced it will release its fourth quarter and full-year ...

1 month ago - GlobeNewsWire

EWING, N.J., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a pharmaceutical technology company, today announced that Robert F. Apple, President and Chief Executi...

2 months ago - GlobeNewsWire

These interesting low-cost stocks have the opportunity to grow.

Other stocks mentioned: FLNT, OPK
3 months ago - The Motley Fool

These companies offer more potential than the stock price might indicate.

Other stocks mentioned: NOK, GSKY
4 months ago - The Motley Fool

EWING, N.J., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a pharmaceutical technology company, today announced that Robert F. Apple, President and Chief Executi...

4 months ago - GlobeNewsWire

EWING, N.J., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a pharmaceutical technology company, today announced that Robert F. Apple, President and Chief Executi...

5 months ago - GlobeNewsWire

Antares Pharma, Inc. (ATRS) CEO Bob Apple on Q3 2020 Results - Earnings Call Transcript

Other stocks mentioned: AAPL
5 months ago - Seeking Alpha

Antares Pharma (ATRS) delivered earnings and revenue surprises of 0.00% and 10.84%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

Antares Pharma (ATRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

5 months ago - Zacks Investment Research

EWING, N.J., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a pharmaceutical technology company, today announced it will release its third quarter 2020 financial ...

5 months ago - GlobeNewsWire

Since my last article in July, Antares has rallied over 20%, finally getting back to the lower end of where it was trading pre-COVID-19.

6 months ago - Seeking Alpha

Antares Expands Urology Portfolio and Leverages Commercial Organization Antares Expands Urology Portfolio and Leverages Commercial Organization

6 months ago - GlobeNewsWire

EWING, N.J., Sept. 08, 2020 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a pharmaceutical technology company, today announced that Robert F. Apple, President and Chief Exec...

7 months ago - GlobeNewsWire

Jack Howarth Retires as Vice President of Corporate Affairs Jack Howarth Retires as Vice President of Corporate Affairs

8 months ago - GlobeNewsWire

Antares Pharma, Inc. (ATRS) CEO Robert Apple on Q2 2020 Results - Earnings Call Transcript

Other stocks mentioned: AAPL
8 months ago - Seeking Alpha

Antares Pharma (NASDAQ: ATRS) shares are trading higher on Monday after the company announced a deal with Lunatus Global to distribute and promote XYOSTED in Saudi Arabia.

8 months ago - Benzinga

EWING, N.J., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS), a pharmaceutical technology company, today announced they have entered into an exclusive distribution agreement with...

8 months ago - GlobeNewsWire

EWING, N.J., July 21, 2020 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“Antares”) (“the Company”), a pharmaceutical technology company, announced the first commercialization of the Compan...

8 months ago - GlobeNewsWire

EWING, N.J., July 20, 2020 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), a pharmaceutical technology company, today announced the appointment of Patrick Shea to the position...

8 months ago - GlobeNewsWire

Antares Continues To Quietly Grow Revenue

9 months ago - Seeking Alpha

EWING, N.J., June 11, 2020 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“the Company”), today announced that Robert F. Apple, President and Chief Executive Officer, will present at the Ray...

10 months ago - GlobeNewsWire

Why is a fast-growing company making one of the best testosterone replacement therapies on the market so underappreciated by investors?

10 months ago - The Motley Fool

Antares Pharma, Inc. (ATRS) CEO Robert Apple on Q1 2020 Results - Earnings Call Transcript

Other stocks mentioned: AAPL
11 months ago - Seeking Alpha

First-quarter financial results failed to spark investors' animal spirits.

11 months ago - The Motley Fool

Antares Pharma: An Undervalued Stock To Buy During The COVID-19 Crisis

1 year ago - Seeking Alpha

Antares Pharma, Inc. (ATRS) CEO Bob Apple on Q4 2019 Results - Earnings Call Transcript

Other stocks mentioned: AAPL
1 year ago - Seeking Alpha

Products from the pharmaceutical technology company continued to pick up momentum in the fourth quarter.

1 year ago - The Motley Fool

Antares Pharma: Reasonable Expectations For 2020

1 year ago - Seeking Alpha

Antares Pharma: XYOSTED's Prescription Growth Is Running On All Cylinders

1 year ago - Seeking Alpha

The Company Expects 2019 Net Revenue at Upper End or Exceed Range of $115 - $120 Million Guidance The Company Expects 2019 Net Revenue at Upper End or Exceed Range of $115 - $120 Million Guidance

1 year ago - GlobeNewsWire

Investors are locking in gains in this fast-growing drugmaker.

1 year ago - The Motley Fool

EWING, N.J., Dec. 10, 2019 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) today announced the appointment of Edward Tykot to the position of Senior Vice President, Corporate Development. Mr. ...

1 year ago - GlobeNewsWire

EWING, N.J., Dec. 06, 2019 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“Antares”) (“the Company”) today announced that the Company’s social media campaign for XYOSTED®, has been honored w...

1 year ago - GlobeNewsWire

Antares' Xyosted Is One Of The Best Testosterone Replacement Therapies Available

1 year ago - Seeking Alpha

Novel Drug Device Combination Product To Be Developed For The Treatment Of Suspected Acute Myocardial Infarction Novel Drug Device Combination Product To Be Developed For The Treatment Of Suspected Acut...

1 year ago - GlobeNewsWire

Novel Drug Device Combination Product To Be Developed For The Treatment Of Suspected Acute Myocardial Infarction Novel Drug Device Combination Product To Be Developed For The Treatment Of Suspected Acut...

1 year ago - GlobeNewsWire

EWING, N.J., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (“Antares” or “Company”) today announced that it has received the final payment of $2.5 million from Ferring Pharmace...

1 year ago - GlobeNewsWire

EWING, N.J., Oct. 24, 2019 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) today announced that data from two poster presentations will be presented on Saturday October 26, 2019 at the 20th An...

1 year ago - GlobeNewsWire

EWING, N.J., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Robert F. Apple, President and Chief Executive Officer, will present at the Ladenburg Thalmann ...

1 year ago - GlobeNewsWire

Every 1% of market share captured by XYOSTED in the testosterone replacement therapy market would grant ATRS $8.5 million in annual sales.

1 year ago - Seeking Alpha

Since the approval of Clarus' TRT drug Jatenzo on March 28, Antares shares have been under pressure, breaking an upward trend to the downside.

1 year ago - Seeking Alpha

Antares Pharma, Inc. (ATRS) CEO Bob Apple on Q1 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Regardless of the company’s growing, diversified portfolio and pipeline of drugs, Antares stock continues to trade like it is a one-product company.

2 years ago - Seeking Alpha

About ATRS

Antares Pharma, Inc., a specialty pharmaceutical company, focuses primarily on the development and commercialization of pharmaceutical products and technologies that address unmet needs in targeted therapeutic areas. It develops, manufactures, and commercialize novel therapeutic products using its drug delivery systems. The company's injection products include XYOSTED for subcutaneous administration of testosterone replacement therapy in adult males; OTREXUP OTREXUP a subcutaneous methotrexate injection indicated for adults with severe active r... [Read more...]

Industry
Medical Instruments & Supplies
IPO Date
Oct 2, 1996
CEO
Robert Apple
Employees
185
Stock Exchange
NASDAQ
Ticker Symbol
ATRS
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 6 analysts, the average rating for Antares Pharma stock is "Strong Buy." The 12-month stock price forecast is 6.42, which is an increase of 60.10% from the latest price.

Price Target
$6.42
(60.10% upside)
Analyst Consensus: Strong Buy